Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Key Points at Issue Listed by Korosho for Discussions on Drug Pricing System Reform
December 14, 2009
- Protein-Mall Kansai Expands Membership
December 14, 2009
- Parliamentary Secretary of Health Objects to GRU Recommendations
December 14, 2009
- Eisai Launches New Oral Jelly Formulation of Aricept
December 14, 2009
- Health Minister Opposed to Exclusion of Kampo Medicines from NHI Coverage
December 14, 2009
- Ichiro Umeda to Take Helm of Pfizer Japan
December 14, 2009
- Large Gap between Korosho's Proposals and MOF's Requirements
December 14, 2009
- Takeda Aims at Entering South American Generics Market
December 14, 2009
- Ordinary NHI Price Cut Rate in FY2010 Expected to Be 6.4%
December 14, 2009
- Otsuka Extends Research Collaboration with Galenea for 1 More Year
December 14, 2009
- Medical Fees Should Be Increased: Mr Sengoku
December 14, 2009
- Hisamitsu to Enhance Operation Efficiency in US
December 14, 2009
- NHI Price Listing OK'd for 23 Products, 12 APIs
December 14, 2009
- Sanofi-aventis to Maintain Same Volume of Sales in 2010: Dr Chocat
December 14, 2009
- GSK Files for Rotavirus Vaccine Rotarix
December 14, 2009
- DSP to Spin Off Animal Health, Food & Speciality Products
December 14, 2009
- FDA Advisory Committee Supports Safety, Efficacy of Prevnar 13
December 14, 2009
- EFPIA Japan Appoints Masuhiro Kato Chairman
December 14, 2009
- More Than 60% of Patients Dissatisfied with Existing Oral Hypoglycemic Agents
December 14, 2009
- No New Safety Measures Required for Lantus: PMDA
December 14, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…